Broder Michael S, Cai Beilei, Chang Eunice, Neary Maureen P
Endocr Pract. 2017 Oct;23(10):1210-1216. doi: 10.4158/EP171879.OR. Epub 2017 Jul 13.
To estimate incidence and prevalence of gastrointestinal neuroendocrine tumors (GI NETs) in U.S. commercially insured patients.
This was a retrospective, cross-sectional study using 2009 to 2014 data from MarketScan and PharMetrics commercial claims databases. Patients were 18 to 64 years old, and had 1 inpatient or 2 outpatient claims with GI NET, identified by International Classification of Diseases, 9th Revision, Clinical Modification codes. Incidence was calculated as number of patients with NET who were disease-free for 2 years prior, divided by number of enrollees and reported as per million person-years (PMPY). Prevalence was calculated as the number of GI NET patients divided by the number of enrollees per year.
The annual number of patients with GI NET ranged from 2,014 to 3,413 in MarketScan and 1,436 to 2,336 in PharMetrics. Incidence increased from 2011 to 2014: 67.0 to 79.1 PMPY in MarketScan and 47.4 to 58.2 PMPY in PharMetrics. Incidence increased by 24.3% in females and 10.7% in males in MarketScan, and by 17.6% in females and 29.3% in males in PharMetrics. Incidence increased with age and was highest in the 45 to 54 and 55 to 64 age groups. Prevalence increased from 77.9 to 131.2 per million per year (MarketScan) and 50.8 to 108.9 (PharMetrics) from 2009 to 2014. Prevalence was generally higher in females than males and highest in 55 to 64 year olds. These increases may be due to better diagnostics, increased awareness of NET among clinicians and pathologists, and/or actual increase in disease.
Clinicians may see GI NET with increasing frequency and should become more familiar with its presentation and treatment.
GI = gastrointestinal; ICD-9-CM = International Classification of Diseases, 9th Revision, Clinical Modification; NET = neuroendocrine tumor; PMPY = per million person-years; SEER = Surveillance, Epidemiology, and End Results.
评估美国商业保险患者胃肠道神经内分泌肿瘤（GI NETs）的发病率和患病率。
这是一项回顾性横断面研究，使用了2009年至2014年MarketScan和PharMetrics商业索赔数据库的数据。患者年龄在18至64岁之间，有1次住院或2次门诊GI NET索赔记录，通过国际疾病分类第九版临床修订本（ICD-9-CM）编码识别。发病率计算为在之前2年无疾病的NET患者数量除以参保人数，并以每百万人口年（PMPY）报告。患病率计算为GI NET患者数量除以每年参保人数。
MarketScan中每年GI NET患者数量在2014至3413例之间，PharMetrics中为1436至2336例。发病率从2011年到2014年有所上升：MarketScan中从67.0 PMPY升至79.1 PMPY，PharMetrics中从47.4 PMPY升至58.2 PMPY。MarketScan中女性发病率上升了24.3%，男性上升了10.7%；PharMetrics中女性发病率上升了17.6%，男性上升了29.3%。发病率随年龄增长而上升，在45至54岁和55至64岁年龄组中最高。患病率从2009年到2014年有所上升，MarketScan中从每年每百万77.9升至131.2，PharMetrics中从50.8升至108.9。患病率总体上女性高于男性，在55至64岁人群中最高。这些上升可能归因于诊断技术的改进、临床医生和病理学家对NET认识的提高，以及/或者疾病实际增加。
临床医生可能会越来越频繁地遇到GI NET，应更加熟悉其临床表现和治疗方法。
GI = 胃肠道；ICD-9-CM = 国际疾病分类第九版临床修订本；NET = 神经内分泌肿瘤；PMPY = 每百万人口年；SEER = 监测、流行病学和最终结果。
